Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Effects of N-3 Fatty Acids on Hepatic Triglyceride Content in Humans

(2016) Gloria Lena Vega et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

(2015) Srinivasan Dasarathy et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Current efforts and trends in the treatment of NASH

(2015) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

(2015) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis

(2015) Chuanyong Guo et al.   Drug Design Development and Therapy

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

(2015) Chuanyong Guo et al.   Drug Design Development and Therapy

By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice

(2015) Weiqi Dai et al.   Oncotarget

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

(2014) Eleonora Scorletti et al.   HEPATOLOGY

Dietary Fucoxanthin Increases Metabolic Rate and Upregulated mRNA Expressions of the PGC-1alpha Network, Mitochondrial Biogenesis and Fusion Genes in White Adipose Tissues of Mice

(2014) Meng-Ting Wu et al.   Marine Drugs

Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis

(2014) Chuanyong Guo et al.   Drug Design Development and Therapy

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

(2013) Z. M. Younossi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis

(2013) J. H. Hoofnagle et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Role of Medications for the Management of Patients with NAFLD

(2013) Natalia Mazzella et al.   Clinics in Liver Disease

Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications

(2013) Giovanni Targher et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT1

(2013) Weiqi Dai et al.   MOLECULAR CARCINOGENESIS

The Relevance of Liver Histology to Predicting Clinically Meaningful Outcomes in Nonalcoholic Steatohepatitis

(2012) Mangesh R. Pagadala et al.   Clinics in Liver Disease

Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?

(2012) Lokpal S. Bhatia et al.   EUROPEAN HEART JOURNAL

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

(2012) Naga Chalasani et al.   GASTROENTEROLOGY

The epidemiology, pathogenesis and histopathology of fatty liver disease

(2012) Adam P Levene et al.   HISTOPATHOLOGY

Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?

(2011) D. Kromhout et al.   EUROPEAN HEART JOURNAL

Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2011) Helen M. Parker et al.   JOURNAL OF HEPATOLOGY

N-3 PUFA Supplementation Triggers PPAR-α Activation and PPAR-α/NF-κB Interaction: Anti-Inflammatory Implications in Liver Ischemia-Reperfusion Injury

(2011) Jessica Zúñiga et al.   PLoS One

Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study

(2010) Francesco Sofi et al.   INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis

(2009) Naoki Tanaka et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

(2009) Curtis K. Argo et al.   JOURNAL OF HEPATOLOGY

Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice

(2008) Hajime Ishii et al.   JOURNAL OF HEPATOLOGY

The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

(2008) Mariana Lazo et al.   SEMINARS IN LIVER DISEASE

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

(2008) Feng-Shang Zhu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

(2007) L. Spadaro et al.   DIGESTIVE AND LIVER DISEASE